Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference

Rhea-AI Summary

Day One Biopharmaceuticals (Nasdaq: DAWN) will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 28 at 11:30 a.m. EST. A live audio webcast of the discussion will be available on the Company’s website, with an archived replay for 30 days.

BRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 35^th Annual Healthcare Conference on Tuesday, November 28 at 11:30 a.m. EST.

A live audio webcast of the discussion will be available by visiting the Events & Presentations section of the Company’s website. An archived replay of the webcast will be available for 30 days following the live presentation.

About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. We put kids first and are developing targeted therapies that deliver to their needs. Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. The Company’s name was inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly-selective type II RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly-selective small molecule inhibitor of mitogen‐activated protein kinases 1 and 2 (MEK-1/-2). Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or Twitter.

DAY ONE MEDIA
Laura Cooper, Head of Communications
media@dayonebio.com

DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com

What time will Day One Biopharmaceuticals participate in the fireside chat at the Piper Sandler Healthcare Conference?

Day One Biopharmaceuticals will participate in the fireside chat at 11:30 a.m. EST on November 28.

Where can I access the live audio webcast of the discussion?

The live audio webcast will be available on the Events & Presentations section of the Company’s website.

How long will the archived replay of the webcast be available?

The archived replay of the webcast will be available for 30 days following the live presentation.